## Non-Motor Manifestations of Parkinson Disease ### Understanding the Correct Answer **Key Point:** Constipation and urinary incontinence do NOT respond reliably to dopaminergic therapy alone. While dopaminergic medications may provide modest benefit, these non-motor complications are multifactorial (involving autonomic dysfunction, reduced gut motility, detrusor hyperreflexia, and sphincter dysfunction) and typically require multimodal management including dietary modification, stool softeners, anticholinergics (for urinary symptoms), and sometimes surgical intervention [cite:Harrison 21e Ch 435]. **Warning:** A common misconception is that optimizing levodopa or dopamine agonists will resolve all non-motor symptoms. In reality, many non-motor features are poorly responsive to dopaminergic therapy and require targeted symptomatic treatment. ### Why the Other Options Are Correct #### REM Sleep Behavior Disorder (RBD) as a Prodromal Marker **High-Yield:** RBD is present in 25–50% of Parkinson disease patients and often precedes motor symptom onset by 5–10 years. It is one of the most specific prodromal markers of synucleinopathy and is associated with Lewy body pathology in brainstem nuclei [cite:Harrison 21e Ch 435]. **Clinical Pearl:** Patients with idiopathic RBD have a 25–50% risk of developing a synucleinopathy (Parkinson disease, dementia with Lewy bodies, or multiple system atrophy) within 10 years. This makes RBD screening valuable in at-risk populations. #### Cognitive Decline and Dementia **Key Point:** Parkinson disease dementia (PDD) develops in approximately 25–30% of patients, typically after motor symptoms have been present for several years. It is characterized by Lewy body pathology extending into the cortex and presents with executive dysfunction, visuospatial impairment, and apathy rather than pure amnesia. | Feature | Parkinson Disease Dementia | Alzheimer Disease | | --- | --- | --- | | Onset relative to motor symptoms | After motor symptoms | Before or concurrent | | Predominant cognitive domain | Executive, visuospatial | Memory | | Pathology | Lewy bodies (cortical) | Amyloid-β, tau tangles | | Hallucinations | Common (visual) | Less common | | Response to cholinesterase inhibitors | Moderate benefit | Better benefit | #### Hyposmia and Anosmia **High-Yield:** Olfactory dysfunction is present in 70–90% of Parkinson disease patients and is one of the earliest non-motor features, often preceding motor symptoms by years. It reflects Lewy body pathology in the olfactory bulb and anterior olfactory nucleus [cite:Harrison 21e Ch 435]. **Clinical Pearl:** Hyposmia in a patient with tremor or rigidity strongly supports Parkinson disease over essential tremor or other parkinsonian syndromes, making it a useful diagnostic clue. ### The Multifactorial Nature of Non-Motor Complications ```mermaid flowchart TD A[Parkinson Disease Pathology]:::outcome --> B[Nigrostriatal Degeneration]:::outcome A --> C[Brainstem Lewy Bodies]:::outcome A --> D[Cortical Lewy Bodies]:::outcome A --> E[Olfactory Bulb Involvement]:::outcome B --> F[Motor symptoms]:::outcome B --> G[Dopaminergic deficit]:::outcome C --> H[RBD, Autonomic dysfunction]:::outcome D --> I[Dementia, Hallucinations]:::outcome E --> J[Hyposmia/Anosmia]:::outcome G --> K[Constipation, Urinary dysfunction]:::outcome H --> K K --> L[Multimodal treatment needed]:::action L --> M[Dopaminergics + Symptomatic therapy]:::action ``` **Mnemonic: NEMO** — **N**on-motor features, **E**arly and **M**ultifactorial, **O**ften requiring treatment beyond dopaminergics. ## Summary Non-motor symptoms in Parkinson disease are diverse, often precede motor symptoms, and reflect widespread Lewy body pathology. While some respond to dopaminergic therapy, many (particularly constipation and urinary dysfunction) require multimodal, targeted symptomatic management.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.